Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 3:54 AM
Ignite Modification Date:
2025-12-25 @ 3:54 AM
NCT ID:
NCT06113302
Brief Summary:
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
Detailed Description:
Objectives:
Primary Objectives:
* To assess the clinical activity and safety of luspatercept in patients with transfusion independent lower risk MDS
* To assess the clinical activity and safety of luspatercept in patients with transfusion dependent lower risk MDS
* To study the effects on hematopoeisis of luspatercept in patients treated on this study
Secondary Objectives:
* To assess the duration of response of patients with treated with luspatercept in this study
* To assess the overall survival and time to transformation of patients with treated with luspatercept in this study
* To assess transfusion free survival period in patients that were transfusion independent treated with luspatercept in this study
* To measure trends in neutrophil and platelet counts in patients treated in this study
Study:
NCT06113302
Study Brief:
Protocol Section:
NCT06113302